PT-141, catalogued in scientific literature under the designation Bremelanotide, is a synthetic cyclic heptapeptide that has been extensively characterized within the domain of peptide chemistry research. As a member of the melanocortin peptide family, it occupies a defined position in analytical and structural peptide studies. This guide is intended strictly for research and laboratory reference purposes, providing a scientifically neutral overview of its chemical composition, manufacturing standards, physicochemical characteristics, and analytical testing protocols. All content herein is presented in alignment with FDA-compliant, non-promotional educational standards for research compounds.
What Is PT-141 Research Peptide?
PT-141 is classified as a synthetic melanocortin peptide analog, structurally derived from the naturally occurring alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike linear peptides, PT-141 adopts a cyclic configuration that distinguishes it from other compounds in its class. In laboratory catalogs, it is indexed under the systematic name Bremelanotide and assigned the molecular formula C50H68N14O10. Its molecular weight is approximately 1025.2 g/mol. The compound is catalogued as a research-grade synthetic peptide and is subject to the same characterization standards applied to other analytical reference materials in peptide science.
PT-141 Peptide Structure and Molecular Characteristics
The structural architecture of PT-141 is defined by its cyclic heptapeptide chain, stabilized through an internal lactam bridge. This cyclization imparts enhanced conformational rigidity relative to linear analogs, a property of considerable interest in structural peptide chemistry. The compound contains key amino acid residues — including D-Phe, Arg, Trp, and Lys — arranged in a configuration that supports its recognition in melanocortin receptor-binding research frameworks.
From a physicochemical standpoint, PT-141 in its lyophilized form presents as a white to off-white amorphous powder. It demonstrates solubility in aqueous buffers under standard laboratory conditions, with solubility profiles documented across varying pH environments. The compound exhibits sensitivity to oxidative conditions, elevated temperatures, and repeated freeze-thaw cycling, all of which are relevant parameters for laboratory handling protocols.
PT-141 Research Peptide Manufacturing Process
Research-grade PT-141 is produced via Solid-Phase Peptide Synthesis (SPPS), a well-established methodology for assembling peptide chains with high sequence fidelity. In SPPS, amino acid residues are sequentially coupled to a solid resin support under controlled reaction conditions, followed by cleavage and side-chain deprotection steps. The resulting crude peptide undergoes multi-stage purification.
Purification is primarily achieved through preparative High-Performance Liquid Chromatography (HPLC), which separates the target peptide from synthesis-related impurities including deletion sequences, truncated fragments, and reagent residuals. Post-purification, the compound is lyophilized to produce a stable, dry powder suitable for long-term laboratory storage. Batch-to-batch consistency is maintained through standardized synthesis parameters and quality control checkpoints throughout the production workflow.
Quality Control and Purity Standards
The quality profile of research-grade PT-141 is established through a comprehensive Certificate of Analysis (COA), which documents analytical data generated from standardized testing procedures. A COA typically includes purity percentage as determined by HPLC, molecular identity confirmation via mass spectrometry, and physical appearance assessment. Research suppliers offering PT-141 / Bremelanotide 10MG formats should provide full COA documentation, including third-party verification where applicable At Element CRP, transparency and analytical reporting standards help support consistent research quality and product integrity.
Purity categories in research peptide characterization commonly range from 95% to 99%+ as assessed by analytical HPLC. Higher purity grades (98-99%+) are preferred for applications in receptor-binding assays and structural studies where background interference from impurity peaks must be minimized. Additional testing parameters include endotoxin content screening (LAL assay), residual solvent analysis (GC headspace), and moisture content determination (Karl Fischer titration). Each of these contributes to a complete analytical profile necessary for rigorous research documentation.
Laboratory Handling and Storage Guidelines
Proper storage of lyophilized PT-141 in a laboratory setting requires adherence to specific environmental conditions to maintain compound integrity over time. The peptide should be stored at -20°C or below in a sealed, desiccated container to prevent moisture uptake and oxidative degradation. Protection from light exposure is recommended, as UV radiation may contribute to peptide bond instability in extended storage.
Freeze-thaw cycling should be minimized to prevent aggregation and physical degradation of the peptide structure. Upon removal from long-term storage, equilibration to ambient temperature prior to handling is advisable. All laboratory manipulations should be conducted within a clean, sterile environment using appropriate containment procedures consistent with good laboratory practice (GLP) standards. Sample integrity logs and usage records should be maintained in compliance with institutional research documentation requirements.
Analytical Testing Methods for PT-141 Research Peptide
The primary analytical method for PT-141 characterization is reverse-phase HPLC (RP-HPLC), which generates a chromatographic purity profile by resolving the target compound from co-eluting impurities based on hydrophobicity. Retention time data, when cross-referenced against authenticated reference standards, provides a reliable identity indicator in addition to the purity metric.
Mass spectrometry, particularly electrospray ionization mass spectrometry (ESI-MS) , is employed for molecular weight confirmation and sequence verification. The observed m/z values are compared to the theoretical mass of the peptide to confirm structural identity. Tandem MS (MS/MS) can further support amino acid sequence confirmation in high-precision analytical workflows. Together, HPLC and MS form the core analytical toolkit for research peptide characterization and are considered industry-standard methods in the field.
Regulatory and Compliance Considerations for Research Peptides
PT-141 is classified strictly as a research compound for laboratory use. It does not hold approval for pharmaceutical, veterinary, or any in vivo application context in standard research procurement frameworks. Suppliers and distributors are expected to maintain clear labeling that reflects its research-only designation, in accordance with applicable regulatory guidelines for non-clinical compounds.
Scientific documentation associated with research peptides, including product pages, COAs, and technical datasheets, must remain neutral with respect to therapeutic or medical framing. Assertions of safety, efficacy, or applicability to human or animal physiology fall outside the permissible scope of research compound characterization. Researchers seeking to understand where to buy PT-141 for laboratory purposes should prioritize suppliers that demonstrate transparent analytical documentation and comply with research compound sourcing standards.
How to Identify High-Quality PT-141 Research Peptide
Evaluating the quality of research-grade PT-141 begins with a thorough review of the supplier-provided Certificate of Analysis. A credible COA will include: the batch or lot number, assay purity by RP-HPLC (expressed as area percentage), molecular weight confirmation by MS, physical description, and testing laboratory identification. Reputable research suppliers will additionally provide third-party testing data, offering an independent verification layer for purity and identity claims.
Other quality indicators include consistent lyophilized appearance (uniform white powder without discoloration or clumping), accurate and compliant labeling (including molecular formula, molecular weight, lot number, and storage requirements), and transparent purity reporting without inflated or unverifiable figures. Procurement from suppliers with documented manufacturing consistency and audit-ready analytical records is the standard expected in research-grade peptide sourcing.
Conclusion
PT-141 (Bremelanotide) represents a well-characterized synthetic cyclic peptide within the broader landscape of melanocortin research compounds. Its defined molecular structure, established synthesis pathway via SPPS, and accepted analytical characterization methods including RP-HPLC and ESI-MS make it a routinely referenced compound in peptide chemistry and analytical research contexts. Proper laboratory handling, rigorous quality verification through COA review, and compliance-centered sourcing practices are foundational to maintaining research integrity when working with this compound.
Researchers and laboratory professionals seeking research-grade peptides with verified analytical documentation are encouraged to work with suppliers that uphold transparent quality assurance standards. Element CRP is one such resource committed to providing research-compliant peptide compounds with full analytical documentation, supporting the scientific community in its pursuit of rigorous, evidence-based laboratory research.
